Healthcare Costs Associated With Newly Diagnosed Type 1 Diabetes in Children With Commercial Health Plan or Medicaid Coverage in US Clinical Practice

Speaker(s)

Halhol S1, Stokes ME2, Li Q3, Cagle A4, Wilson L4
1Evidera, Paris, Île-de-France, France, 2Evidera, Montreal, QC, Canada, 3Evidera, Boston, MA, USA, 4Sanofi, Bridgewater, NJ, USA

OBJECTIVES: To estimate healthcare costs in newly diagnosed paediatric patients with type 1 diabetes (T1D) in US clinical practice.

METHODS: We retrospectively analyzed Merative MarketScan® data for newly diagnosed paediatric patients with T1D (1-Jan-2014–30-Jun-2019). Patients with ≥2 T1D claims ≥30 days apart (first claim was index date), ≥12 months of pre-index enrolment, ≥1 month of follow-up post-index, and <18 years at index were included. Outcomes were T1D-related per-patient per-month (PPPM) costs by health plan (Commercial and Medicaid) and by time since diagnosis.

RESULTS: We identified 4092 Commercial and 1153 Medicaid patients (mean [SD] age: 10.5 [4.3] vs 11.1 [4.1] years; 44.5% vs 51.4% female; median follow-up: 24.7 vs 27.9 months); total T1D-related costs incurred were $34,628 and $ 23,517, respectively. T1D-related PPPM costs were highest during the initial 3 months (Commercial: $4563 vs Medicaid: $1741) after diagnosis (3–6 months: $1019 vs $742; 6–12 months: $1080 vs $791; 12–18 months: $886 vs $776; 18–24 months: $853 vs $837). Inpatient hospitalizations (including for diabetic ketoacidosis) accounted for 55% (Commercial) and 37% (Medicaid) of costs during the initial three months (3–6 months: 3.7% and 1.8%; 6–12 months: 9.3% and 7.6%; 12–18 months: 6.1% and 8.2%; 18–24 months: 6.4% and 13.8%). Insulin and equipment accounted for 23.9% (Commercial) and 46.7% (Medicaid) of costs during the first 3 months (3–6 months: 81.6% vs 85.8%; 6–12 months: 76.0% vs 84.9%; 12–18 months: 78.1% vs 82.8%; 18–24 months: 78.9% vs 78.5%).

CONCLUSIONS: Costs (excluding rebates and co-payments etc.) in the 3 months after diagnosis were over 2.5-times higher in Commercial patients than Medicaid patients. In the first 3 months, inpatient stays (including for diabetic ketoacidosis) contributed proportionately more to Commercial costs than to Medicaid, while insulin and equipment contributed proportionately more in Medicaid patients.

Code

RWD181

Topic

Economic Evaluation, Real World Data & Information Systems, Study Approaches

Topic Subcategory

Health & Insurance Records Systems

Disease

Diabetes/Endocrine/Metabolic Disorders (including obesity)